B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interactions in the lymph node niches. To identify miRNA expression changes in the CLL microenvironment, we performed complex profiling of short noncoding RNAs in this context by comparing CXCR4/CD5 intraclonal cell subpopulations (CXCR4dimCD5bright vs CXCR4brightCD5dim cells). This identified dozens of differentially expressed miRNAs, including several that have previously been shown to modulate BCR signaling (miR-155, miR-150, and miR-22) but also other candidates for a role in microenvironmental interactions. Notably, all 3 miR-29 family members (miR-29a, miR-29b, miR-29c) were consistently down-modulated in the immune niches, and lower miR-29(a/b/c) levels associated with an increased relative responsiveness of CLL cells to BCR ligation and significantly shorter overall survival of CLL patients. We identified tumor necrosis factor receptor-associated factor 4 (TRAF4) as a novel direct target of miR-29s and revealed that higher TRAF4 levels increase CLL responsiveness to CD40 activation and downstream nuclear factor-κB (NF-κB) signaling. In CLL, BCR represses miR-29 expression via MYC, allowing for concurrent TRAF4 upregulation and stronger CD40-NF-κB signaling. This regulatory loop is disrupted by BCR inhibitors (bruton tyrosine kinase [BTK] inhibitor ibrutinib or phosphatidylinositol 3-kinase [PI3K] inhibitor idelalisib). In summary, we showed for the first time that a miRNA-dependent mechanism acts to activate CD40 signaling/T-cell interactions in a CLL microenvironment and described a novel miR-29-TRAF4-CD40 signaling axis modulated by BCR activity.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Internal Medicine 1 Medical University of Vienna Vienna Austria; and

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Medical Oncology Dana Farber Cancer Institute Boston MA

Department of Pathology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Science Masaryk University Brno Czech Republic

Moores Cancer Center Department of Medicine University of California San Diego La Jolla CA

See more in PubMed

Kipps TJ, Stevenson FK, Wu CJ, et al. . Chronic lymphocytic leukaemia [published correction in Nat Rev Dis Primers. 2017;3:17008]. Nat Rev Dis Primers. 2017;3(1):16096. PubMed

Ondrisova L, Mraz M. Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol. 2020;10:591577. PubMed PMC

Pavlasova G, Borsky M, Seda V, et al. . Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609-1613. PubMed PMC

Calissano C, Damle RN, Marsilio S, et al. . Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17(11-12):1374-1382. PubMed PMC

Pavlasova G, Borsky M, Svobodova V, et al. . Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018;32(9):2028-2031. PubMed

Herndon TM, Chen SS, Saba NS, et al. . Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017;31(6):1340-1347. PubMed PMC

Herishanu Y, Pérez-Galán P, Liu D, et al. . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574. PubMed PMC

D’Avola A, Drennan S, Tracy I, et al. . Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016;128(6):816-826. PubMed

Rossmann ED, Jeddi-Tehrani M, Osterborg A, Mellstedt H. T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stage. Leukemia. 2003;17(11):2252-2254. PubMed

Palmer S, Hanson CA, Zent CS, et al. . Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008;141(5):607-614. PubMed PMC

Scielzo C, Apollonio B, Scarfò L, et al. . The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia [published correction in Leukemia. 2011:25:1794]. Leukemia. 2011;25(11):1760-1767. PubMed

Schleiss C, Ilias W, Tahar O, et al. . BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci Rep. 2019;9(1):701. PubMed PMC

Lezina L, Spriggs RV, Beck D, et al. . CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM. Blood Adv. 2018;2(15):1869-1881. PubMed PMC

Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood. 1992;80(12):3173-3181. PubMed

Ahearne MJ, Willimott S, Piñon L, et al. . Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. Br J Haematol. 2013;162(3):360-370. PubMed

Pascutti MF, Jak M, Tromp JM, et al. . IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013;122(17):3010-3019. PubMed

Bagnara D, Kaufman MS, Calissano C, et al. . A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011;117(20):5463-5472. PubMed PMC

Cui B, Chen L, Zhang S, et al. . MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-554. PubMed PMC

Mraz M, Chen L, Rassenti LZ, et al. . miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014;124(1):84-95. PubMed PMC

Palacios F, Abreu C, Prieto D, et al. . Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia. 2015;29(1):115-125. PubMed

Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2015;29(5):1004-1017. PubMed

Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835-840. PubMed PMC

Dorsett Y, McBride KM, Jankovic M, et al. . MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity. 2008;28(5):630-638. PubMed PMC

O’Connell RM, Baltimore D. MicroRNAs and hematopoietic cell development. Curr Top Dev Biol. 2012;99:145-174. PubMed

Henao-Mejia J, Williams A, Goff LA, et al. . The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity. 2013;38(5):984-997. PubMed PMC

Mraz M, Kipps TJ. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia [published correction in Leuk Lymphoma. 2014;55(4):969]. Leuk Lymphoma. 2013;54(8):1836-1839. PubMed PMC

Vigorito E, Perks KL, Abreu-Goodger C, et al. . microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847-859. PubMed PMC

Koralov SB, Muljo SA, Galler GR, et al. . Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008;132(5):860-874. PubMed

Ebert PJ, Jiang S, Xie J, Li QJ, Davis MM. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol. 2009;10(11):1162-1169. PubMed PMC

Li G, Yu M, Lee WW, et al. . Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med. 2012;18(10):1518-1524. PubMed PMC

Calin GA, Ferracin M, Cimmino A, et al. . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801. PubMed

Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. . microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113(21):5237-5245. PubMed

Rossi S, Shimizu M, Barbarotto E, et al. . microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116(6):945-952. PubMed PMC

Fulci V, Chiaretti S, Goldoni M, et al. . Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007;109(11):4944-4951. PubMed

Mraz M, Malinova K, Kotaskova J, et al. . miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23(6):1159-1163. PubMed

Mraz M, Dolezalova D, Plevova K, et al. . MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012;119(9):2110-2113. PubMed

Calin GA, Dumitru CD, Shimizu M, et al. . Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524-15529. PubMed PMC

Klein U, Lia M, Crespo M, et al. . The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40. PubMed

Cimmino A, Calin GA, Fabbri M, et al. . miR-15 and miR-16 induce apoptosis by targeting BCL2 [published correction in Proc Natl Acad Sci USA. 2006;103(7):2464]. Proc Natl Acad Sci USA. 2005;102(39):13944-13949. PubMed PMC

Cerna K, Oppelt J, Chochola V, et al. . MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33(2):403-414. PubMed

Musilova K, Devan J, Cerna K, et al. . miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood. 2018;132(22):2389-2400. PubMed

Tili E, Michaille JJ, Luo Z, et al. . The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood. 2012;120(13):2631-2638. PubMed PMC

Guinn D, Ruppert AS, Maddocks K, et al. . miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib. Leukemia. 2015;29(5):1210-1213. PubMed PMC

Guinn D, Lehman A, Fabian C, et al. . The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. Cancer Med. 2017;6(4):778-787. PubMed PMC

Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma. 2009;50(3):506-509. PubMed

Pekarsky Y, Santanam U, Cimmino A, et al. . Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-11593. PubMed

Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26(42):6133-6140. PubMed PMC

Leich E, Zamo A, Horn H, et al. . MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118(20):5550-5558. PubMed PMC

Zhao JJ, Lin J, Lwin T, et al. . microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010;115(13):2630-2639. PubMed PMC

Zhang X, Zhao X, Fiskus W, et al. . Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell. 2012;22(4):506-523. PubMed PMC

Mraz M, Malinova K, Mayer J, Pospisilova S. MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 2009;390(1):1-4. PubMed

Kollinerova S, Vassanelli S, Modriansky M. The role of miR-29 family members in malignant hematopoiesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(4):489-501. PubMed

Chang TC, Yu D, Lee YS, et al. . Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50. PubMed PMC

Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244(1):115-133. PubMed PMC

Bishop GA. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol. 2004;4(10):775-786. PubMed

Herman SE, Gordon AL, Hertlein E, et al. . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296. PubMed PMC

Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017;31(12):2601-2607. PubMed

Cerna K, Mraz M. p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1. Oncotarget. 2018;9(92):36409-36410. PubMed PMC

Kminkova J, Mraz M, Zaprazna K, et al. . Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis. 2014;35(5):992-1002. PubMed PMC

Akbari Moqadam F, Pieters R, den Boer ML. The hunting of targets: challenge in miRNA research. Leukemia. 2013;27(1):16-23. PubMed

Arvey A, Larsson E, Sander C, Leslie CS, Marks DS. Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol. 2010;6(1):363. PubMed PMC

Shi C, Rao C, Sun C, et al. . miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis. Cell Death Dis. 2018;9(11):1078. PubMed PMC

Paiva C, Rowland TA, Sreekantham B, et al. . SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;102(11):1890-1900. PubMed PMC

Munzert G, Kirchner D, Stobbe H, et al. . Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002;100(10):3749-3756. PubMed

Zapata JM, Krajewska M, Morse HC III, Choi Y, Reed JC. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA. 2004;101(47):16600-16605. PubMed PMC

Xie P, Kraus ZJ, Stunz LL, Bishop GA. Roles of TRAF molecules in B lymphocyte function. Cytokine Growth Factor Rev. 2008;19(3-4):199-207. PubMed PMC

Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J Exp Med. 2004;199(5):661-671. PubMed PMC

Bishop GA, Hostager BS, Brown KD. Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J Leukoc Biol. 2002;72(1):19-23. PubMed

Arcipowski KM, Stunz LL, Graham JP, Kraus ZJ, Vanden Bush TJ, Bishop GA. Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem. 2011;286(12):9948-9955. PubMed PMC

Zhang X, Wen Z, Sun L, et al. . TRAF2 regulates the cytoplasmic/nuclear distribution of TRAF4 and its biological function in breast cancer cells. Biochem Biophys Res Commun. 2013;436(2):344-348. PubMed

Rousseau A, McEwen AG, Poussin-Courmontagne P, et al. . TRAF4 is a novel phosphoinositide-binding protein modulating tight junctions and favoring cell migration. PLoS Biol. 2013;11(12):e1001726. PubMed PMC

Li JM, Fan LM, Christie MR, Shah AM. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol. 2005;25(6):2320-2330. PubMed PMC

Li W, Peng C, Lee MH, et al. . TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 2013;73(23):6938-6950. PubMed PMC

Kédinger V, Alpy F, Baguet A, et al. . Tumor necrosis factor receptor-associated factor 4 is a dynamic tight junction-related shuttle protein involved in epithelium homeostasis [published correction appears in PLoS One. 2008;3(11):e882]. PLoS One. 2008;3(10):e3518. PubMed PMC

Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1993;85(3):439-445. PubMed

Garzon R, Liu S, Fabbri M, et al. . MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411-6418. PubMed PMC

Luo W, Weisel F, Shlomchik MJ. B cell receptor and CD40 signaling are rewired for synergistic induction of the c-Myc transcription factor in germinal center B cells. Immunity. 2018;48(2):313-326. PubMed PMC

Landau DA, Sun C, Rosebrock D, et al. . The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8(1):2185. PubMed PMC

Chiang CL, Goswami S, Frissora FW, et al. . ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. Blood. 2019;134(5):432-444. PubMed PMC

Thijssen R, Slinger E, Weller K, et al. . Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302-e306. PubMed PMC

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs

In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia